Iperereza kuri Saxenda na Ozempic imiti ikoreshwa mu kugabanya ibiro ariko igatera kwiyahura.
Zimwe mu nshinge zitera kugabanya ibiro nyuma yo gukeka ko zinatera kwiyahura ziri gukorerwa isuzuma n’ikigo cy’ubugenzuzi bw’imiti mu Burayi.
Saxenda na Ozempic imiti ikoreshwa mu kugabanya ibiro, igihugu cya Iceland, cyaburiye urwego rugenzura ubuvuzi mu Burayi European Medecines Agency (EMA) ko iyi miti inatera imitekerereze yo kwiyahura , nyuma yo kubona ubwandu butatu, ndetse uyifata akaba yanakwigirira nabi.
Umuyobozi wa Komite y’urwego rwa EMA ishinzwe gusuzuma ibyago bituruka ku miti, ku ikubitiro izasuzuma ibyago bishingiye ku muti utera kugabanya ibiro ufite ubumara buzwi nka semaglutide cyangwa liraglutide ,nyuma yo kubona ubwandu bugera kuri butatu bwagaragajwe n’urwego rw’ubuvuzi muri Iceland. Ibi bimenyetso byagaragajwe birimo n’ibitekerezo byo kwiyahura no kwikomeretsa nyuma yo gukoresha umuti wa Saxenda na Ozempic. EMA izatanga amakuru arambuye namara kuboneka
Ikimenyetso ni amakuru mashya cyangwa ingaruka zisanzwe zizwi zishobora guterwa n’umuti kandi zigomba gukorerwa iperereza ryimbitse. PRAC, nayo iri gukora iri suzuma, izareba niba ubundi buvuzi buri mu rwego rugari rusa n’ubu, nk’ubushingiye ku misemburo ituruka mu rwagashya, nabwo bukeneye isuzuma ryimbitse.
Ku isi imiti iracyari micyeya.
Ku mbuga nkoranyambaga hacaho ubutumwa butandukanye cyane ubw’ibyamamare bitakaza ibiro byinshi bwatumye haba ubwinshi bw’abashaka ubu buvuzi.
Saxenda na Wegovy ni imiti yemewe kandi yemerewe kugabanya ibiro. Umuhangayiko cyangwa ibitekerezo byo kwiyahura bikubiye mu makuru ajyana n’imiti, agira inama abayikoresha ko: Wagombye kwitondera impinduka izo ari zo zose mu buryo wiyumva mu mutwe,imyifatire, ibitekerezo cyangwa imbamutima.
“Hamagara uguha ubuvuzi ako kanya niba ugize impinduka nshya mu mutwe cyangwa mbi kurushaho cyangwa ziguhangayikishije.”
Imiti yose ishobora kugira ibyago by’ingaruka mbi. Ku miti igabanya ibiro, yagombye gufatanwa n’indyo yuzuye kandi n’imyitozo. Zimwe mu ngaruka zizwi cyane harimo :
Gucika intege, kubabara umutwe ,impiswi ,gutumba mu nda ,kuribwa mu gifu ,umunaniro no kuruka.
Abatanga iyi miti nabo bagirwa inama yo kugenzura niba uruganda rwa Novo Nordisk rukora uwo muti ruri gukorana n’urwego rwa EMA kandi ruvuga ko umutekano w’abarwayi ari wo uri ku isonga. Uruhagarariye yagize ati:
“GLP-1 wakoreshejwe mu kuvura abantu indwara ya diyabete yo mu bwoko bwa kabiri mu gihe cy’imyaka irenga 15 ndetse n’ubuvuzi bw’umubyibuho ukabije mu myaka umunani irimo n’imiti ya Novo Nordisk nka semaglutide na liraglutide iri ku isoko mu Bwongereza kuva muri 2018 na 2019.
Amakuru ashingiye ku mutekano w’imiti yakusanyijwe muri gahunda y’igerageza rigari ndetse n’ubugenzuzi bwakozwe nyuma yo kuyamamaza ntibwerekanye ihuriro hagati ya semaglutide cyangwa liraglutide n’ibitekerezo byo kwiyahura cyangwa kwigirira nabi.
“Novo Nordisk irakomeza kugenzura aya makuru ari mu magerageza y’ubuvuzi ndetse n’uburyo imiti yayo ikoreshwa kandi ikorana bya hafi n’abategetsi mu kwizeza ko umutekano w’abarwayi n’amakuru aboneye ku bavuzi nk’uko nbcnew.com yabivuze.
“Urwego rwa EMA, rurakomeza kugenzura ibimenyetso by’amakuru y’umutekano kandi na Novo Nordisk irabikora. Novo Nordisk ikomeje kwiyemeza umutekano w’abarwayi ndetse n’urwego rugenzura imiti mu Bwongereza (MHRA), rwavuze ko ruri kugenzura ibi bintu.
Dr Alison Cave, umuyobozi w’urwego rw’umutekano w’abarwayi muri MHRA, yavuze ko nka kimwe mu bigize ubugenzuzi bwabo, ibimenyetso bishya bigaragaye bisuzumirwa hamwe n’andi makuru, arimo n’uburyo imiti ishobora gutera ibibazo. Nibiba ngombwa , ngo tuzatanga inama nshya ku batanga ubuvuzi n’abarwayi. Yatanze inama kubafata imiti bakagira ibitekerezo by’ubwiyahuzi cyangwa byo kwigirira nabi, ko bagomba kwihutira gushaka ubufasha kwa muganga.